7 billion 500 million! Luoxin pharmaceutical, a well-known pharmaceutical company, went through backdoor listing and was approved

7 billion 500 million! Well known pharmaceutical companies, approved for backdoor listing ▍ Luoxin pharmaceutical, about to be listed on December 17, Dongyin shares issued a notice, Luoxin pharmaceutical, approved for backdoor listing According to the announcement, China Securities Regulatory Commission (hereinafter referred to as "CSRC") Review Committee of merger and reorganization of listed companies (hereinafter referred to as "merger and reorganization committee") held the 69th working meeting of the merger and reorganization committee in 2019, and purchased assets and related transactions for major assets replacement and issuance of shares of Zhejiang Dongyin Pump Industry Co., Ltd (hereinafter referred to as "the company") Item was reviewed According to the audit results of the meeting, the company's major asset replacement and issue of shares to purchase assets and related transactions have been conditionally approved Generally speaking, Luoxin pharmaceutical, which has been delisted from Hong Kong stock exchange for nearly 4 years, will be listed on the back door After the completion of this transaction, the controlling shareholder of Dongyin Co., Ltd was changed to Luo Xin Holding Co., Ltd., which held 37.17% of the shares of the listed company, and the actual controller of the listed company was changed to Liu Baoqi and Liu zhenteng and his son It is understood that 99.65476% of the equity of Luoxin Pharmaceutical Co., Ltd is to be invested in this major asset restructuring Based on the assessed value as of December 31, 2018, the transaction price of the assets to be placed is RMB 7.538 billion, which is determined by the parties to the transaction through consultation Prior to this transaction, the main business of Dongyin Co., Ltd is R & D, production and sales of well used submersible pump, small submersible pump and onshore pump; after the transaction, Dongyin Co., Ltd will transform into a pharmaceutical manufacturing industry, and its main business is R & D, production and sales of pharmaceutical products ▍ after the delisting of Hong Kong stock, the public information of A-share listing shows that Luoxin pharmaceutical is a large pharmaceutical enterprise group integrating drug R & D, production, sales and medical and health services, with R & D and innovation as the core driving force of enterprise development There was a view in the industry that Luoxin pharmaceutical was the first case in recent years when Hong Kong stock was successfully privatized and delisted, and then listed in A-share backdoor The profitability of Luoxin pharmaceutical industry is also widely concerned by the industry In 2016, 2017 and 2018, the net profits of Luoxin pharmaceutical industry attributable to the owners of the parent company were 426 million yuan, 466 million yuan and 512 million yuan, respectively In the restructuring plan, both parties of this transaction also made performance commitments The net profit of Luoxin pharmaceutical in 2019, 2020 and 2021 will not be less than RMB 550 million, RMB 650 million and RMB 750 million, respectively ▍ with strong R & D ability, Luoxin Pharmaceutical Co., Ltd has 48 new drug certificates and 6 class 1 new drugs under research, mainly focusing on digestive, respiratory and anti-tumor products Among them, the highest proportion of R & D projects is in the field of anti-tumor (photo source: gronhui) from the perspective of product progress, rohin pharmaceutical has more than 90 projects under research, including 28 main products under research, cypress blue, which are inquired on the Internet The consistency of ambroxol hydrochloride tablets, cefradine capsules and Cefalexin Capsules of rohin pharmaceutical has been evaluated Today (December 18), rohin pharmaceutical released the news that after three years, its product, captopril tablet (25mg), has been approved by the State Food and Drug Administration and passed the conformity assessment of generic drugs That is to say, so far, four drugs under the company have passed the conformity assessment of generic drugs Because of the consistent evaluation of generic drugs and the continuous implementation of the new bidding rules, the trend of medical insurance fund turnover is unstoppable More and more innovative drugs are covered Chinese pharmaceutical companies have increased their investment in innovative research and development to explore how to change from mature products to innovative products Especially after Hengrui, the leading pharmaceutical company, announced to stop generic drug research and development, the capital market also preferred enterprises with strong innovation ability and growth According to wind data, in 2018, there were 429 R & D personnel in Luoxin pharmaceutical industry, with R & D investment accounting for 8.45% of the operating revenue, both higher than the average number of R & D personnel in the same industry and the average R & D investment in the same industry in the same period The capital market made a certain response to the listing of Luoxin pharmaceutical According to the data, the backdoor transaction triggered the market's pursuit of Dongyin shares The share price of Dongyin shares once climbed to 15 yuan / share in the secondary market, a new high since 2018 ▍ it should be noted that the active layout of API business shows that rosin pharmaceutical is the only approved API manufacturer in China at present The maximum capacity of ambroxol hydrochloride API in Roxin pharmaceutical industry can reach 120 tons / year, which is in the forefront of the industry It has a competitive advantage in the quality and production cost of cefotiam hydrochloride API and lansoprazole API Luoxin pharmaceutical API plant has passed the AFM site certification in Japan and the official audit of MFDs in South Korea in 2016 With the expansion and implementation of national procurement with volume, the demand for enterprises' production capacity is higher and higher If the winning enterprise does not have the ability to produce APIs, it is not only limited in the ability to bid and offer, but also may have great uncertainty in its "carrying capacity" performance ability and profit space However, enterprises with advantages in raw materials will be more likely to occupy a seat in the competition Cypress blue will continue to pay attention to the future development of rohin pharmaceutical industry.